BofA analyst Alec Stranahan raised the firm’s price target on CG Oncology (CGON) to $84 from $72 and keeps a Buy rating on the shares. Shares have run up 62% year-to-date with the acceleration of the timeline for PIVOT-006 IR NMIBC data, notes the analyst, who is “still bullish at current levels” and sees “more room to run.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology Appoints Veteran Jim DeTore as Chief Financial Officer
- JPMorgan healthcare analysts hold an analyst/industry conference call
- CG Oncology price target raised to $100 from $80 at H.C. Wainwright
- CG Oncology price target raised to $90 from $60 at UBS
- Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology